Evaluation of the safety and tolerability of re-dosing with intravenous (iv) otelixizumab in newly diagnosed adult subjects with type 1 diabetes mellitus.

Trial Profile

Evaluation of the safety and tolerability of re-dosing with intravenous (iv) otelixizumab in newly diagnosed adult subjects with type 1 diabetes mellitus.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 01 Sep 2017

At a glance

  • Drugs Otelixizumab (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Adverse reactions
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 20 Apr 2012 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
    • 17 Jun 2011 Actual initiation date (Nov 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top